Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses
- PMID: 33755731
- PMCID: PMC8083771
- DOI: 10.1093/infdis/jiab161
Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses
Abstract
Background: We investigated frequency of reinfection with seasonal human coronaviruses (HCoVs) and serum antibody response following infection over 8 years in the Household Influenza Vaccine Evaluation (HIVE) cohort.
Methods: Households were followed annually for identification of acute respiratory illness with reverse-transcription polymerase chain reaction-confirmed HCoV infection. Serum collected before and at 2 time points postinfection were tested using a multiplex binding assay to quantify antibody to seasonal, severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike proteins and SARS-CoV-2 spike subdomains and N protein.
Results: Of 3418 participants, 40% were followed for ≥3 years. A total of 1004 HCoV infections were documented; 303 (30%) were reinfections of any HCoV type. The number of HCoV infections ranged from 1 to 13 per individual. The mean time to reinfection with the same type was estimated at 983 days for 229E, 578 days for HKU1, 615 days for OC43, and 711 days for NL63. Binding antibody levels to seasonal HCoVs were high, with little increase postinfection, and were maintained over time. Homologous, preinfection antibody levels did not significantly correlate with odds of infection, and there was little cross-response to SARS-CoV-2 proteins.
Conclusions: Reinfection with seasonal HCoVs is frequent. Binding anti-spike protein antibodies do not correlate with protection from seasonal HCoV infection.
Keywords: COVID-19; SARS-CoV-2; antibody; correlates of protection; household cohort; immunity; reinfection; seasonal coronavirus; serology; waning.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Figures




Similar articles
-
Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.Front Immunol. 2021 Jul 27;12:696370. doi: 10.3389/fimmu.2021.696370. eCollection 2021. Front Immunol. 2021. PMID: 34386006 Free PMC article.
-
Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015-20: a surveillance study.Lancet Microbe. 2021 Mar;2(3):e105-e114. doi: 10.1016/S2666-5247(20)30221-4. Epub 2021 Jan 27. Lancet Microbe. 2021. PMID: 33937883 Free PMC article.
-
Epidemiological and co-infection characteristics of common human coronaviruses in Shanghai, 2015-2020: a retrospective observational study.Emerg Microbes Infect. 2021 Dec;10(1):1660-1668. doi: 10.1080/22221751.2021.1965498. Emerg Microbes Infect. 2021. PMID: 34350810 Free PMC article.
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
-
An overview on the seven pathogenic human coronaviruses.Rev Med Virol. 2022 Mar;32(2):e2282. doi: 10.1002/rmv.2282. Epub 2021 Aug 2. Rev Med Virol. 2022. PMID: 34339073 Review.
Cited by
-
Association between the Seroprevalence of Antibodies against Seasonal Alphacoronaviruses and SARS-CoV-2 Humoral Immune Response, COVID-19 Severity, and Influenza Vaccination.J Clin Med. 2023 Feb 21;12(5):1733. doi: 10.3390/jcm12051733. J Clin Med. 2023. PMID: 36902520 Free PMC article.
-
Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination.J Virol. 2023 Mar 30;97(3):e0166422. doi: 10.1128/jvi.01664-22. Epub 2023 Feb 13. J Virol. 2023. PMID: 36779758 Free PMC article.
-
Respiratory Viral Infections From 2015 to 2022 in the HIVE Cohort of American Households: Incidence, Illness Characteristics, and Seasonality.J Infect Dis. 2025 Mar 17;231(3):795-804. doi: 10.1093/infdis/jiae423. J Infect Dis. 2025. PMID: 39179953 Free PMC article.
-
PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.mSphere. 2022 Jun 29;7(3):e0017922. doi: 10.1128/msphere.00179-22. Epub 2022 May 19. mSphere. 2022. PMID: 35586986 Free PMC article.
-
Great Expectations of COVID-19 Herd Immunity.mBio. 2022 Feb 22;13(1):e0349521. doi: 10.1128/mbio.03495-21. Epub 2022 Jan 25. mBio. 2022. PMID: 35073740 Free PMC article.
References
-
- Drosten C, Günther S, Preiser W, et al. . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967–76. - PubMed
-
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous